ClinicalTrials.Veeva

Menu
M

Mid Atlantic Retina Specialists | Hagerstown, MD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aflibercept
APL-2
Dexamethasone
Axitinib
EYP-1901
Sunitinib Malate
ANX007
GB-102
BI 771716
Bevacizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 16 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS 01 as compared to Vehicle...

Active, not recruiting
Diabetic Macular Edema
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Drug: Vehicle

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Enrolling
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: OTX-TKI
Drug: Aflibercept

Trial sponsors

Jaeb Center for Health Research logo
A
Bayer logo
AbbVie logo
A
Boehringer Ingelheim logo
C
E
G
Ocular Therapeutix logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems